Kornimate/medical-research-clean huggingface dataset:
the effect of therapeutic play applied by using toy nebulizer and toy mask on child's fear and anxiety level

Conditions: Therapeutic Play; Anxiety; Fear

Summary: in this study, it was aimed to examine the effect of therapeutic play applied with a toy nebulizer and toy mask before inhaler treatment on children's fear and anxiety. it is the hypothesis of the study that the therapeutic play applied by using a toy mask and a toy nebulizer before inhaler treatment in children will reduce the child's fear and anxiety.

acute diseases constitute the majority of applications made to pediatric emergency services. inhaled drugs are frequently used in the treatment of childhood acute respiratory system diseases. nebulizers are the preferred method of administering inhaled drugs. medical procedures are one of the biggest fears of children, making it difficult to use nebulizers correctly and effectively. the negative reaction of the child to the mask and nebulizer during inhaler treatment causes incorrect inhalation patterns, reducing the safety and effectiveness of the treatment. this causes difficulties in relieving symptoms, increased hospital admission and hospitalization time, more treatment costs, and even negative consequences such as increased morbidity. reducing the fear and anxiety seen in children due to the hospital environment and illness is important in terms of children's acceptance of the treatment process. one of the methods used for this purpose is therapeutic play. pediatric nurses should fulfill their nursing roles and responsibilities by including therapeutic play in their care processes.

Eligibility criteria:
inclusion criteria: 1. parent and child volunteering to participate in the study, 2. the child is between the ages of 3-8, 3. being admitted due to respiratory system disease, 4. inhaler treatment with a nebulizer will be applied. exclusion criteria: 1. parent and child not voluntarily participating in the study, 2. intravenous, intramuscular or any other treatment request, 3. the child has any genetic, congenital, chronic or metabolic disease, 4. the child has vision, hearing and speech problems, 5. the child's vital signs are unstable (no fever, tachypnea, etc.) and the need for any emergency intervention.

Keywords: toy mask toy nebulizer child nurse
emotion focused internet delivered treatment for adults with eating disorders

Conditions: Eating Disorders

Summary: the goal of this clinical trial is to develop and test a new internet delivered treatment for adult patients with eating disorders, focused on developing normalized eating patterns and emotion regulation skills. the main focus is to investigate the additional effect of emotion regulation interventions, beyond the effect of other central tratment components normally included in evidence based eating disorder treatment. the internet delivered treatment is divided into two phases, phase a and phase b. phase a focus on establishing normalised eating patterns, and in phase b the emotion regulation interventions are added. participants will get access to treatment modules every third day over a time period of 8.5 weeks, each module consist of psychopedagogical material, excercises and home work. data will be collected via the online research platform every third day during the treatment. data is also collected at more comprehensive assessment points pre-treatment, post-treatment, and follow up 3 months after end of treatment.

this study uses an experimental single-case design, specifically a randomized replicated ab design. the baseline lenght (i.e., phase a) is randomized for each participant. there is six possible assignments, as the randomization is restricted to give all participants minimum 8 and maximum 12 treatment modules in each phase, with minimum 9 and maximum 14 baseline assessment points.

Eligibility criteria:
inclusion criteria: * dsm5 eating disorder * minimum 18 years old * ongoing contact with a psychiatric clinic in sweden exclusion criteria: * body mass index below 18,5 * somatic instability due to eating disorder severeness * high risk of suicide or severe self-harm * ongoing addiction or substance abuse * ongoing psychological treatment or psychotherapy * new or changed mediciation for psychiatric disorders in the past 2 months * planned or ongoing pregnancy or recently gave birth

Keywords: eating disorder treatment emotion regulation treatment internet treatment
international prospective multicenter study on radiation dose estimates of coronary ct angiography in daily practice

Conditions: Coronary Disease

Summary: estimation of radiation dose of coronary multislice computed tomography (msct) angiography in daily practice in an international, multicenter and vendor-independent trial.

prospective analysis of cardiac ct angiographies enrolled over 1 month collection of 1 axial data set and the "patient dose protocol" (including kv, mas, ctdi, dlp, etc.) on a cd dose estimation in dose/cm with the use of a method proposed by the european working group for guidelines on quality criteria in ct. assessment of diagnostic, qualitative image quality on a per-vessel basis by the participating study sites and in randomly selected cases by the primary study investigators (approximately 5-10% of patients to "spot check" interobserver variability of image quality assessments) assessment of image quality with the use of quantitative parameters including image noise, signal-to-noise and contrast-to-noise ratios

Eligibility criteria:
inclusion criteria: * assessment of coronary arteries * acute chest pain or "triple rule out" * evaluation after pci (stents) * evaluation of bypass grafts * before or after ep study * cardiac anomalies exclusion criteria: * pregnancy * contraindications against contrast media

Keywords: coronary ct angiography radiation dose estimates
comparing ngenuity vs conventional microscope in a new hydrus user

Conditions: Glaucoma

Summary: to compare the potential efficiency and educational value of using ngenuity (3d camera system, fda approved for this indication) vs the conventional microscope for hydrus microstent placement by new users.


Eligibility criteria:
inclusion criteria: * patients with mild to moderate primary open angle glaucoma as defined by ags with visually significant age-related cataract undergoing uncomplicated cataract surgery and hydrus microstent * either eye or both eyes may participate exclusion criteria: * lack of patient cooperation severely affecting ability to place stent with any visualization technique * angle abnormalities including pas in nasal quadrant * unable to properly visualize the angle due to complicated cataract surgery
effectiveness of multicomponent treatment for fibromyalgia (fibrowalk)

Conditions: Fibromyalgia

Summary: the main objective of this study is to analyse the effectiveness of the fibrowalk multicomponent treatment program as coadjuvant of treatment-as-usual (tau) compared to tau alone.

this is a two-arm rct focused on the potential efficacy of the multicomponent program fibrowalk as coadjuvant of treatment-as-usual (tau) vs. tau alone. fibrowalk combines multicomponent approach based on pain neuroscience education (pne), therapeutic exercise, cognitive behavioural therapy (cbt) and mindfulness training. the main objective of this rct was two-fold: (a) to analyse the effectiveness of a 12-week multicomponent treatment as an add-on to treatment (fibrowalk) as usual (tau) to improve functional impact (primary outcome), as well as pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) compared to tau; and (b) to explore the baseline differences between responders and non-responders in terms sociodemographic and clinical characteristics.

Eligibility criteria:
inclusion criteria: 1. fulfil the 2010/2011 american college of rheumatology (acr) fm diagnostic criteria. the diagnosis was verified by a rheumatologist (ma) of the csssu 2. adults \> 18 years old, and 3. provide written informed consent. exclusion criteria: 1. to have a terminal illnesses or programmed interventions that might interrupt the study. 2. no stringent eligibility criteria were established due to the naturalistic nature of the rct. excluding patients with lower education or comorbidities might have turned away many patients from our rct who would otherwise be eligible, that is we put emphasis on external validity. all recruited patients were considered capable of following the multicomponent therapy if they were allocated to it. lack of adherence to drugs or home activities was not an exclusion criterion given the nature of our trial and we analysed data from all participants who underwent random allocation. treatment allocation was performed by the clinical trials unit in accordance with computer-generated randomisation sequences.

Keywords: multicomponent treatment chronic pain fibromyalgia pain neuroscience education therapeutic exercise cognitive behavioural therapy mindfulness randomized controlled trial
study of subcutaneous epcoritamab in combination with intravenous rituximab and oral lenalidomide (r2) to assess adverse events and change in disease activity in adult participants with follicular lymphoma

Conditions: Follicular Lymphoma (FL)

Summary: follicular lymphoma (fl) is the second most common b-cell cancer and the most common type of cancer of lymphocytes. unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. this study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (r2) in treating adult participants with relapsed or refractory (r/r) fl. adverse events and change in disease condition will be assessed. epcoritamab is an investigational drug being developed for the treatment of fl. study doctors put the participants in 1 of 3 groups, called treatment arms. each group receives a different treatment. enrollment to one of the groups is closed. around 500 adult participants with r/r fl will be enrolled in approximately 300 sites across the world. participants will receive r2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status score 0 to 2. * participant has: * fluorodeoxyglucose-positron emission tomography (fdg-pet) scan demonstrating positive lesion compatible with computed tomography (ct) or magnetic resonance image (mri)-defined anatomical tumor sites and * \>= 1 measurable nodal lesion (long axis \> 1.5 cm) or \>= 1 measurable extra-nodal lesion (long axis \> 1.0 cm) on ct scan or mri. * histologically confirmed classic follicular lymphoma (fl) \[previously grade 1 to 3a fl\] stage ii, iii, or iv with no evidence of histologic transformation to an aggressive lymphoma and cd20+ disease on most recent representative tumor biopsy based on the pathology report. * relapsed or refractory (r/r) disease to at least one prior systemic regimen that contained an anti-cd20 monoclonal antibody (mab) in combination with chemotherapy. (participant who received only prior anti-cd20 mab monotherapy and/or radiation therapy is not eligible.) * eligible to receive r2 per investigator determination. * estimated creatinine clearance (crcl) \>= 50 ml/min. exclusion criteria: * documented refractoriness to lenalidomide. * have lenalidomide exposure within 12 months prior to randomization.

Keywords: follicular lymphoma (fl) non-hodgkin's lymphoma (nhl) lymphoma cancer epcoritamab rituximab lenalidomide epcore fl-1 epcore
neurocognitive features of patients with treatment-resistant depression

Conditions: Treatment Resistant Depression

Summary: there is an urgent need for novel and effective interventions for treatment-resistant depression (trd). in previous studies, ketamine has been shown to rapidly reduce depressive symptoms; however, the exact mechanisms of action of ketamine remain unknown. there are some preliminary findings to suggest that ketamine may exert its antidepressant effects through promotion of neurogenesis in the dentate gyrus. the aim of this study is to help delineate the neurocognitive effects of ketamine exposure using a behavioral task (specifically, a pattern separation task) and a battery of other well-established cognitive measures. this is an assessment-only study, as we will be recruiting subjects to complete an assessment battery at two time points, before and after receiving ongoing ketamine administrations for at least four weeks.


Eligibility criteria:
inclusion criteria: 1. be 18-80 years old 2. be able to read, understand, and provide written informed consent in english, 3. meet criteria for a current moderate/severe (\> 14 on qids-sr) depressive episode (unipolar or bipolar mood disorder), 4. have a history of \> 3 failed antidepressant trials, and be 5. be seeking ketamine ongoing treatment through the ketamine clinic at massachusetts general hospital and be deemed appropriate for the clinic. exclusion criteria: 1. subjects who will not provide consent to neuropsychological testing 2. subjects who are not deemed appropriate for the ketamine clinic will not be enrolled
map( mean arterial pressure) and mortality relation in patients with heart failure

Conditions: Heart Failure

Summary: aim of this observational study is to evaluate the relationship between mean arterial pressure (map) and mortality in patients presenting to the emergency department with acute heart failure, focusing on emergency department monitoring and subgroup presentations. our goal is to determine the impact of subgroup characteristics on mortality among patients presenting with heart failure in the emergency department, and to assess the predictive value and significance of map in predicting mortality.

after obtaining ethical approval, the study will commence within 2 weeks and continue for 1 year. based on clinical statistics or general literature data, and considering sample size calculations, a total of 280 patients across 4 groups have been determined. inclusion criteria: age 18 and above patients presenting with symptoms of heart failure exclusion criteria: age under 18 patients presenting with st-elevation myocardial infarction patients with acute kidney failure pregnant patients patients with inaccessible data for the parameters under study groups based on initial mean arterial pressure (map) upon hospital admission will be established as follows: \ 100 mmhg. data including results of emergency department tests and pertinent findings will be recorded for patients in these groups. the 30-day mortality rates of these patients will be statistically evaluated based on their map values and the procedures performed during emergency department monitoring.

Eligibility criteria:
inclusion criteria: age 18 and above patients presenting with symptoms of heart failure exclusion criteria: age under 18 patients presenting with st-elevation myocardial infarction patients with acute kidney failure pregnant patients patients with inaccessible data for the parameters under study

Keywords: heart failure mean arterial pressure emergency department
effectiveness of video monitoring and care transition for heart failure patients (evit-hf): randomized clinical trial

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)

Summary: the goal of this clinical trial is to measure the effectiveness of video monitoring associated with the transition of care for patients with heart failure. the main questions it aims to answer is: is video monitoring superior to monitoring via audio calls in patients with heart failure? researchers will compare monitoring by video to a monitoring by audio to see if drug videomonitoring works to improve selfcare in heart failure and other outocomes. participants will: intervention group receive video calls guided by cardiologist nurses at 7, 30, 60, 180 and 365 days after hospital discharge. the control group will receive audio calls for data collection, at the same time mentioned.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older; * admitted for decompensated hfref * ejection fraction less than 40% confirmed by echocardiogram performed in the last 3 months * who access to a mobile device with internet access exclusion criteria: * heart transplant waiting list; * who had undergone coronary artery bypass in the last 3 months ; * who were in palliative care; * who had a life expectancy of less than 1 year

Keywords: heart failure nursing care clinical trial telenursing
diagnosis and therapy of vulnerable atherosclerotic plaque

Conditions: Carotid Atherosclerosis; Stroke; Type 2 Diabetes; Metabolic Syndrome

Summary: the aim of the present study is to examine the atherosclerotic plaque stability using in vivo and in vitro techniques and to investigate the influence of exercise, anti-diabetic, lipid-lowering and cannabinoids receptor antagonists on atherosclerotic plaque texture in patients with cardiovascular risk and animals prone to atherosclerosis.


Eligibility criteria:
inclusion criteria: * carotid atherosclerosis * femoral atherosclerosis * cardiovascular risk exclusion criteria: * heart failure * renal disease * liver disease * life-threatening diseases

Keywords: cardiovascular events
evaluation of the long-term hepatitis a and b antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with gsk biologicals' combined hepatitis a and b vaccine, twinrix® (sb208127) in study hab-084 (208127/084)

Conditions: Hepatitis B; Hepatitis A

Summary: the purpose of this study is to assess the long-term persistence of immunity to hepatitis a and b in adults who were vaccinated 16-20 years earlier with the combined hepatitis a and hepatitis b vaccine, twinrix.


Eligibility criteria:
inclusion criteria: * subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * a male or female who received two/three doses of twinrix according to his/her group allocation in study hab-084 (208127/084), and received no further dose of any hepatitis a and/or b vaccine since then. * written informed consent obtained from the subject. exclusion criteria: * chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to study entry. inhaled and topical steroids are allowed. * administration of long-acting immune-modifying drugs within six months prior to the study entry. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device). * administration of any hepatitis a and/or b vaccine at any time since completion of the primary vaccination series in hab-084 (208127/084) study, including a challenge dose of the study vaccine, as a part of the study procedures, during the long-term persistence phase. * documented history of hepatitis a or b disease since completion of the primary vaccination series in hab-084 (208127/084) study. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * administration of immunoglobulins within six months prior to study entry.

Keywords: twinrix long-term follow-up persistence hepatitis a antibody immunity hepatitis b combination vaccine adult
efficacy of deep transcranial magnetic stimulation (tms) for treatment-resistant depression and neuroanatomical correlates: a clinical study coupled with positon emission tomography (pet)

Conditions: Pharmacoresistant Depression

Summary: repetitive transcranial magnetic stimulation (tms) is an emergent non-invasive treatment for treatment resistant depression (trd). the exact neuro-functional mechanisms related to tms efficiency remains however unknown; besides local effect on the target, tms may induce interaction changes between remote cerebral regions. on the other hand, few studies have been performed in comparison to sham placebo stimulation. the investigators recently showed that non-responder depressive patients to tms exhibited deeper and wider brain functional abnormalities hardly reachable by standard coils. the h1-coil is a novel tms (h-tms) device capable of inducing a magnetic field with a deeper and wider distribution than standard coils. the investigators design here a randomized controlled study in which the investigators will compare the clinical effects of h-coil tms and standard tms in patients with trd, and their functional neuroanatomical correlates and changes in connectivity by positron emission tomography (pet). the general objective is to better understand the mechanisms related to tms efficiency in pharmacoresistant depression, in order to propose the best therapeutic approach for the patient.


Eligibility criteria:
inclusion criteria: * patients who met the diagnosis of major depressive episode (mde) * patient right-handed * men and women aged over 18 years with major depressive episode iv (dsm-iv criteria), isolated or recurrent. * scores on the scale madrs\> 20 * resistance criterion defined as the failure of two antidepressants effective dose for a minimum of six weeks. * drug therapy stable for at least 2 weeks exclusion criteria: * bipolar disorder type i or type ii * depression with psychotic features * diagnosis according comorbid axis i (dsm iv) with schizophrenia, alcohol abuse and / or toxic substances. * inpatient under stress or under legal protection measure (guardianship, curatorship) * counter to the practice of transcranial magnetic stimulation : a personal history of seizure, history of neurological or neurosurgical pathologies, metallic prosthetic material or foreign objects (pacemakers, prosthetic eye equipment, etc.). * pregnant or breastfeeding ongoing. * somatic disorder may affect cognitive abilities and brain structures * known allergy to any component of fludeoxyglucose

Keywords: pharmaco-resistant depressed patients